Key result
Concomitant use of intravenous fluoroquinolones vs beta-lactams in warfarin users was associated with a higher risk of excessive anticoagulation (INR ratio >2.5; 95% CI 1.59-46.5).
Why the study?
The influence of antibiotic type and Bacteroides fragilis susceptibility on warfarin anticoagulation had not been clarified in clinical settings.
Does the use of fluoroquinolones or antibiotics active against Bacteroides fragilis increase the risk of excessive anticoagulation in warfarin users compared to beta-lactams or non-susceptible antibiotics?
Cohort (n=1,185)
No
Does the use of fluoroquinolones or antibiotics active against Bacteroides fragilis increase the risk of excessive anticoagulation in warfarin users compared to beta-lactams or non-susceptible antibiotics?
Concomitant use of fluoroquinolones or antibiotics active against Bacteroides fragilis in warfarin users is associated with a higher risk of excessive anticoagulation.
May support closer INR monitoring with IV fluoroquinolones in warfarin users; leaves open causality and extension to other agents.
Background: The difference in type of antibiotics and susceptibility of Bacteroides fragilis to antibiotics may influence warfarin anticoagulation. However, these influences have not been clarified in clinical settings. Objectives: This study aimed to investigate association the between the prothrombin time–international normalized ratio (PT-INR) and concomitant use of antibiotics in a real-world population of warfarin users. Methods: This was a single-center cohort study using data from health records and included patients who received β-lactams (BLs)/fluoroquinolones (FQs) during ongoing warfarin treatment (2011-2015) at Hamamatsu University Hospital in Japan. Antibiotics were categorized into those to which B fragilis is susceptible (BL sus , FQ sus ) and those to which it is not (BL non , FQ non ) and into those given orally (BL po , FQ po ) or intravenously (BL iv , FQ iv ). Outcomes were excessive PT-INR and changes in PT-INR, defined as the ratio (INR ratio) and difference (ΔINR) of maximum PT-INR and baseline PT-INR. Excessive PT-INR was graded as INR ratio of >1.5 or >2.5. Results: A total of 1185 warfarin users were included. The proportion of INR ratio >2.5 in FQ iv was higher than in BL iv (95% CI: 1.59-46.5). The proportions with an INR ratio of >1.5 in BL sus and FQ sus were higher than in BL non (1.72-14.1) and FQ non (1.05-9.36), respectively. ΔINR values in FQ po , FQ iv , and FQ sus were higher than those in BL po , BL iv , and FQ non , respectively. Conclusions and Relevance: Concomitant use of FQs, or of antibiotics to which B fragilis is susceptible is associated with higher risk of excessive anticoagulation. These findings would contribute to safe and proper antibiotic treatment in warfarin users.
No takes yet. Share an insight, caveat, or question.
Yagi et al. (2020) conducted a cohort in Warfarin users requiring antibiotics (n=1,185). Fluoroquinolones and B fragilis-susceptible antibiotics vs. Beta-lactams and B fragilis-nonsusceptible antibiotics was evaluated on Excessive PT-INR (INR ratio >1.5 or >2.5) and changes in PT-INR (95% CI 1.59-46.5). Concomitant use of intravenous fluoroquinolones vs beta-lactams in warfarin users was associated with a higher risk of excessive anticoagulation (INR ratio >2.5; 95% CI 1.59-46.5).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: